With the launch of trials.cancer.gov, the National Cancer Institute hopes that making clinical trial information more user-friendly will result in greater awareness and participation in clinical trials to move the science forward faster.
There's one provision of the Affordable Care Act that hasn't gotten much attention outside the industry, but it's a significant one: providers face financial penalties when a patient is readmitted more than 30 days after treatment.
With the belief that suicide deaths for individuals under the care of a provider should be preventable, behavioral health specialists have set a goal that is both audacious and aspirational.
More than half of men 50 years of age and older, and up to 90 percent of men over 80 are affected by symptoms of benign prostatic hyperplasia BPH, or enlarged prostate, which can significantly impact quality of life.
During a man's lifetime, odds are one in seven that he be diagnosed with prostate cancer. If it's a slower growing form detected in later years, he may live out a normal life span and die with it, but not from it.
A wave of excitement swept through medical science in 2003 when the first sequencing of the human genome was completed. News stories were full of enthusiastic predictions of a revolution in health care.
For patients with advanced stage cancer, time is life.
HudsonAlpha Institute for Biotechnology has joined 13 of the nation's top cancer research centers in the Oncology Research Information Exchange Network® (ORIEN), a collaboration to accelerate clinical development and discovery of treatments for advanced-stage cancers.
Almost half of women in the United States suffer from symptoms of declining estrogen, including the uncomfortable condition of vaginal atrophy. The atrophy causes thinning, drying and inflammation of the vaginal walls which leads to painful intercourse and problems with urination.
The landmark Alzheimer's Disease Neuroimaging Initiative (ADNI) began in October 2004 with a goal of finding more sensitive and accurate methods to detect Alzheimer's disease (AD) in the early stages and to track progression by identifying and monitoring biomarkers. Last month, the NIH's National Institute on Aging announced an award of approximately $40 million over the next five years to launch ADNI3.
For most physicians, difficult conversations come with the territory.
After the initial shock of hearing a serious diagnosis and absorbing what the prognosis could mean, the next question patients often ask is why. Why me? Why now?
Cardiologists at UAB Hospital are the first in Alabama to treat coronary artery disease patients with a new dissolving heart stent. The Abbott's Absorb bioresorbable vascular scaffold (BVS), FDA approved for use in July, gradually dissolves and may be a safer option for patients in the future.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: